This study aimed to investigate impacts of Omicron infection on cancer patients in China. A retrospective study was conducted, including 347 cancer patients undergoing radiotherapy or chemoradiotherapy between July 2022 and March 2023. Three groups involved: 108 patients without SARS-CoV-2 infection (non-COVID-19 group), 102 patients beginning treatment 10?days after first SARS-CoV-2 infection (≥?10?days COVID-19 group), and 137 patients beginning treatment less than 10?days after first SARS-CoV-2 infection (10?days COVID-19 group). SAA, hsCRP, ALT, etc., were used to assess COVID-19 infection. Serum levels of SAA, hsCRP and IL-6 were all raised in two COVID-19-infected groups (SAA?0.01, hsCRP?0.01, IL-6?0.05), but PCT, ALT, LDH and HBDH levels were only elevated in?≥?10?days COVID-19 group (PCT?=?0.0478, ALT?=?0.0022, LDH?=?0.0313, HBDH?=?0.0077). Moreover, moderate and severe infected cases were higher in?≥?10?days COVID-19 group than?10?days COVID-19 group (12/102 vs 5/137, p?=?0.0211), but no significance in myelosuppression and completion rates among three groups. Omicron infection led to inflammation, liver and cardiovascular injury on cancer patients, but delay duration of radiotherapy or chemoradiotherapy after infection did not affect the completion rates and myelosuppression of current therapy. Besides, severity of Omicron infection was even worse among cancer patients who received delayed treatment.
Completion rates and myelosuppression degrees of cancer patients receiving radiotherapy or chemoradiotherapy unchanged regardless of delay duration after Omicron infection
- 期刊:Scientific Reports
- 阅读原文
待确认